Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering-Plough shipping Gyne-Lotrimin 3 within days of July 29 approval.

This article was originally published in The Tan Sheet

Executive Summary

SCHERING-PLOUGH SHIPPING GYNE-LOTRIMIN 3 TO TRADE following FDA's July 29 approval of the three-day OTC vaginal yeast infection treatment. The company said it plans to begin shipments of the clotrimazole product within days of the approval. Unlike other recently launched three-day treatments, Gyne-Lotrimin 3 is not an Rx-to-OTC switch product since it was never available as an Rx dosage regimen. Schering filed an NDA in September 1994.

Topics

UsernamePublicRestriction

Register

PS085890

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel